India Market Update 2026 Generic Semaglutide in India 2026 Following patent expiry on 20 March 2026, multiple Indian pharmaceutical companies have launched generic semaglutide injections
For clinicians, its an opportunity to better tailor obesity treatment: we can now choose between two excellent medications, considering factors like efficacy needed, comorbid conditions, side effect profiles, and patient preference
Successfully navigating these common side effects should be viewed not just as a way to improve comfort, but as a core component of the overall strategy for healthy weight loss on GLP-1 medications
What does affect results is consistency
Ive been struggling with this for so many years and have never been given such clear and easy answers
In fact, they work better together, boosting each others antioxidant effects